TuHURA Biosciences (HURA) investor relations material

Executive summary

• Focused on developing immuno-oncology therapies, with lead candidates IFx-2.0 and TBS-2025 in clinical development targeting resistance to cancer immunotherapies.

• Advanced all programs with key milestones targeted for the second half of 2026, including regulatory feedback and trial initiations.

• No product revenue; operations funded by equity, debt, and grants.

• Secured a $50 million term credit facility, extending cash runway into 2028.

• Net losses continue as R&D and G&A expenses rise with clinical progress and public company costs.

Financial highlights

• Net loss for Q2 2026 was $9.2 million, compared to $9.5 million in Q2 2025; net loss for the six months ended June 30, 2026 was $16.8 million, up from $16.2 million year-over-year.

• Research and development expenses increased to $6.6 million in Q2 2026 from $4.9 million in Q2 2025, driven by clinical development and higher personnel costs.

• General and administrative expenses rose to $2.1 million in Q2 2026 from $1.9 million in Q2 2025, mainly due to stock compensation and public company costs.

• Cash and cash equivalents were $1.0 million as of June 30, 2026.

• Net cash outflows from operating activities were ($13.0) million for the first half of 2026, compared to ($10.9) million in the prior year period.

Outlook and guidance

• Existing capital resources, including a $50 million revolving credit facility, expected to fund operations into the end of 2028.

• Anticipates continued operating losses as clinical programs advance; substantial additional funding will be needed for future growth and development.

• Topline results from the IFx-2.0 Phase 3 trial expected in the second half of 2027.

• Anticipates FDA safe-to-proceed feedback and initiation of Phase 1b/2 trial for VISTA in mutNPM1 r/r AML in 2H 2026.

• Expects orphan drug designation for IFX-2.0 in MCC and TBS-2025 in AML in 2H 2026.